CryoLife receives FDA approval for PerClot clinical trial

theflyonthewall.com

Company said, "During the quarter we made significant progress in advancing our new product initiatives, enhancing our long-term growth potential. We received FDA approval to begin our pivotal clinical trial for PerClot in surgical settings, followed by 510 clearance for PerClot Topical. We are now positioned to launch PerClot Topical in the Q2. We also secured the distribution rights to the ProCol Vascular Bioprosthesis, a vascular access graft that is complementary to the HeRO Graft. In Asia, we established a new regional headquarters in Singapore, which will allow us to more effectively bring our expanding portfolio of medical device products to the high-growth Asia-Pacific region."

View Comments (0)